Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment after epidermal growth factor receptor EGFR tyrosine kinase inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Falk, Markus, Schatz, Stefanie, Reich, Fabian P. M., Schmidt, Stefanie, Galster, Marco, Tiemann, Markus, Ficker, Joachim H., Brueckl, Wolfgang M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605132/
https://www.ncbi.nlm.nih.gov/pubmed/37887540
http://dx.doi.org/10.3390/curroncol30100640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605132/
https://www.ncbi.nlm.nih.gov/pubmed/37887540
http://dx.doi.org/10.3390/curroncol30100640

Ejemplares similares